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ABSTRACT
Inactivation of SMAD4 has been linked to several
cancers and germline mutations cause juvenile
polyposis (JP). We set out to identify the promoter(s)
of SMAD4, evaluate their activity in cell lines and
define possible transcription factor binding sites
(TFBS). 50-rapid amplification of cDNA ends
(50-RACE) and computational analyses were used
to identify candidate promoters and corresponding
TFBS and the activity of each was assessed by
luciferase vectors in different cell lines. TFBS were
disrupted by site-directed mutagenesis (SDM) to
evaluate the effect on promoter activity. Four pro-
moters were identified, two of which had significant
activity in several cell lines, while two others had
minimal activity. In silico analysis revealed multiple
potentially important TFBS for each promoter. One
promoter was deleted in the germline of two JP
patients and SDM of several sites led to significant
reduction in promoter activity. No mutations were
found by sequencing this promoter in 65 JP
probands. The predicted TFBS profiles for each of
the four promoters shared few transcription factors
in common, but were conserved across several
species. The elucidation of these promoters and
identification of TFBS has important implications
for future studies in sporadic tumors from multiple
sites, and in JP patients.
INTRODUCTION
SMAD4 is a tumor suppressor gene that is essential for
transforming growth factor b (TGFb) signalling (1), which
plays important roles in cell differentiation, growth and
apoptosis. It is the human ortholog of the Drosophila Mad
(mothers against decapentaplegic) and Caenorhabditis
elegans sma-4 genes. Originally called DPC4 (deleted in
pancreatic cancer 4) due to the ﬁnding that the majority
of pancreatic cancers have 18q allelic loss (2), it was later
renamed SMAD4 to better reﬂect its orthology to its
worm and ﬂy gene counterparts (3). It is the common
intracellular mediator for the TGFb, bone morphogenetic
protein (BMP), activin and inhibin pathways. Its role is to
form oligomers with receptor regulated SMAD proteins
(SMAD1, 2, 3, 5 and 8) phosphorylated after the binding
of ligand to the Types II and I cell surface receptors, then
these complexes migrate to the nucleus to regulate tran-
scription of target genes (4,5).
A variety of human cancers have been shown to have
loss of heterozygosity at the SMAD4 locus on chromo-
some 18q21, including 50% of pancreatic cancers (6,7),
41% of cervical cancers (8,9), >60% of colorectal
cancers (10), 25% of small intestinal cancers (11), 27%
of thyroid cancers (12) and 60% of gastric carcinomas
(13). Furthermore, up to 21% of juvenile polyposis (JP)
patients have germline mutations in SMAD4 (14,15).
The promoter regions of genes are important regulatory
regions for RNA and protein expression and may play a
role in many diseases. Studies of SMAD4 gene regulation
have been limited thus far. Minami et al. (16) suggested
that the region immediately upstream from the
50-untranslated region (50-UTR) and ﬁrst coding exon
had promoter activity. A later report found two substitu-
tions in endometrial cancers within this proposed
promoter region (17). Roth et al. (18) screened a region
about 14kb upstream from this putative promoter, but
did not ﬁnd evidence of methylation in colorectal cancer
specimens. Other groups did ﬁnd methylation within
the region examined by Roth et al. (18) in tumors
from patients with esophageal adenocarcinoma (19) and
in prostate cancers (20). Kloth et al. (9) screened
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region in cervical cancer specimens, but did not ﬁnd
methylation.
Although Minami et al. (16) and Zhou et al. (17)
performed limited functional assays of one potential
promoter, no studies have systematically examined
SMAD4 mRNA isoforms to identify additional transcrip-
tional start sites (TSS) and their corresponding promoters.
It is becoming increasingly apparent that genes are
commonly regulated by multiple promoters, allowing for
ﬂexibility of gene expression in different tissues and envir-
onments (21). The purpose of this study was to fully
characterize the promoter regions located upstream of
the 50-UTR by 50-rapid ampliﬁcation of cDNA ends
(RACE), computational analysis and functional studies
with luciferase reporter assays and to further study these
regions for potential TFBS that could be altered by
germline mutations or epigenetic modiﬁcations leading
to the genesis of human cancer. Furthermore, we wanted
to screen JP probands that did not have mutations in the
coding regions of SMAD4 and BMPR1A, the two genes
known to cause JP (14,22), to ﬁnd out if mutations in a
SMAD4 promoter might account for additional cases
of JP.
MATERIALS AND METHODS
RNA extraction and 50-RACE
RNA was extracted from lymphoblastoid cell lines (LCLs;
created from peripheral blood leukocytes from our JP
patients at the Baylor College of Medicine, Department
of Molecular and Human Genetics Tissue Culture Core
Laboratory), normal colon tissue and colon polyps from
a JP patient, using RNeasy miniprep columns (Qiagen,
Valencia, CA, USA). The cDNA was created using
gene-speciﬁc primers (GSP) using the Invitrogen
50-RACE kit (Carlsbad, CA, USA) as per the manufactur-
er’s instructions. Successive rounds of ampliﬁcation were
performed using GSP1 chosen in coding SMAD4 exon 4
(30-CCAAGTAATCGTGCATCG-50), GSP2 in coding
exon 2 (30-GATCTATGCCCGTCTCTGGA-50), GSP3
in coding exon 1 (30-CCTGAATACATGTCTAAC
AA-50) and GSP4 in the 50-UTR (30-CCTGAATACATG
TCTAACAATTTTCCT-50). The cDNA products were
then cloned into the Topo 2.1 vector (Invitrogen) and
recombinant clones were sequenced.
In Silico analysis
The Genomatix software suite (www.genomatix.de) was
used for computational analysis. Gene2Promoter
was ﬁrst used to identify putative promoter regions, then
MatInspector identiﬁed all TFBS matching a database of
pre-deﬁned matrix descriptions. The comparative
genomics feature of Eldorado allowed the analysis of a
group of SMAD4 orthologous genes across species.
Common TFBS were then processed through
FrameWorker to deﬁne groups of sites that occur in a
speciﬁc order and are separated by a certain distance
across the orthologous sequences. The genomic sequences
upstream from the non-coding (NC) exons 1, 3, 4 and
50-UTR of SMAD4 were obtained using the UCSC
Genome Browser (www.genome.ucsc.edu) assembly
GRCh37/hg18 from March 2006.
Plasmid construction and site-directed mutagenesis
Primers were designed using Primer3 v. 0.4.0 (http://frodo
.wi.mit.edu/) to clone the four potential promoter regions.
To create the deletion constructs, successively shorter
PCR products were ampliﬁed from genomic DNA using
increasingly closer 50 primers and the same 30 primer.
All primers used had the Mlu1 endonuclease site
incorporated at the 50-end and the BglII site at the
30-end in order to clone the sequence into the pGL3
luciferase basic reporter vector (Promega, Madison, WI,
USA). Deletion constructs were cloned into the pGL3
vector and transformed into Escherichia coli and recom-
binant plasmids were veriﬁed by direct sequencing.
Luciferase assays
The normal human colon ﬁbroblast cell line CRL-1459,
human embryonic kidney cell line HEK-293, breast cancer
cell line MCF-7 and human colon cancer cell line
CCL-247 were obtained from the American Type
Culture Collection (Manassas, VA, USA) and cultured
according to the ATCC recommendations. The transfec-
tion mix consisted of 5mg of pGL3/deletion construct
insert, 1mgo fRenilla control vector with CMV
promoter (pRL-CMV; Promega), 36ml of Transfast
reagent and minimum essential media (MEM) without
serum for a total volume of 1ml. Prior to adding the trans-
fection mix, 5 10
5 cells from each cell line were added to
6-well plates (Corning, NY, USA) in MEM with 10%
serum and penicillin/streptomycin/amphotericin (PSA)
and grown to 80–90% conﬂuence. One milliliter of trans-
fection mix was added to each well and allowed to
incubate for 4h. After the incubation, 2ml of MEM
with 10% serum and PSA were added to each well and
the cells allowed to grow for 72h. All deletion constructs
from each promoter plus the pGL3-basic vector (without
insert) were co-transfected with the pRL-CMV control
vector in triplicate. Cells were then harvested and
assayed using the Dual-Luciferase reporter assay kit
(Promega). The ﬁnal amount of ﬁreﬂy luciferase activity
for each construct was determined by subtracting the
background ﬁreﬂy luciferase activity from the control
pGL3 basic vector without construct and then
normalizing to the Renilla luciferase activity for each
individual reaction.
Screening for promoter genetic alterations
The promoter region with the greatest luciferase activity
and upstream from the greatest number of transcripts
discovered by 50-RACE was then sequenced in 65
JP probands that did not have coding mutations of
SMAD4 or BMPR1A or large exonic deletions by multi-
plex ligation-dependent probe ampliﬁcation (MLPA;
MRC Holland, Amsterdam). Two individuals were previ-
ously described to have a large deletion by MLPA at the
50-end of SMAD4 (15). One of these deletions was further
characterized to identify the breakpoints using an
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(CGH) chip (HG18_WG_CGH_7 of 8 array; NimbleGen
Systems, Madison, WI, USA), which has probes spaced
approximately every 700bp.
Chromatin immunoprecipitation sequencing and DNaseI
hypersensitivity sites
MCF-7 cells were grown in MEM supplemented with 10%
FBS and were harvested at 80–90% conﬂuence to obtain
8 10
7 cells. Cells were then cross-linked with 1% formal-
dehyde for 10min at room temperature, the cell pellet was
then resuspended in ChIP lysis buffer with complete
protease inhibitor tablet (Roche), then sonicated to
produce chromatin fragments approximately 350 bases
in length. Five micro grams of Anti-RNA Pol II (mouse
monoclonal, Cat No: 17-620, Millipore) were added and
incubated overnight at 4 C. The antibody/protein/DNA
complexes were eluted and complexes treated with 10mg
RNase A and 0.3M NaCl at 67 C for 4h to reverse the
cross-links. DNA/proteins were precipitated, the proteins
were digested in proteinase K, then the DNA puriﬁed
with a QIAGEN PCR puriﬁcation column. The
ChIP-enriched DNA was then prepared for Chromatin
immunoprecipitation sequencing (ChIP-Seq) and
short-read sequencing performed using the Illumina
GA2 sequencing system. The raw sequencing images
were analyzed using the Illumina analysis pipeline and
reads were aligned to the human reference genome
(NCBI v36, hg18). ChiP-seq data for other cell lines and
Digital DNaseI-Seq were obtained from the ENCODE
Project Consortium (23).
Determining relative abundance of each NC isoform
Total RNA was extracted from CRL-1459, MCF-7 and
HEK-293 cells using the RNeasy kit (Qiagen), then
transferred to a nitrocellulose membrane and UV
cross-linked. Oligos were designed for each of ﬁve
SMAD4 NC exon splice variants, which spanned across
adjacent NC exons, adjacent NC exon and 50-UTR, or
50-UTR (Probe 1: 50-GTATTCAGGATAACTAACCTG
CTTTAAGTTGGC-30; Probe 2: 50-GACATGTATTCA
GGATAACCCTCTCCCCG-30; Probe 3: 50-ATTCAGG
ATAACAGATTCTCTGAGTCAGGATTC-30; Probe 4:
50-ATGTATTCAGGATAACCTGGGCTCGGGCGG-30;
Probe 5: 50-TTGGTGTATTCGTAATAGACATATTGT
CCAT-30). Each oligo was end-labelled with [g32P]-ATP
using T4 Polynucleotide Kinase, then hybridized to the
membranes in conjunction with denatured salmon sperm
DNA. Blots were washed, exposed to ﬁlm and relative
concentrations determined using a Typhoon FLA 7000
(General Electric).
RESULTS
NC splice variants of SMAD4
50-RACE revealed that there were four NC exons
upstream of the 50-UTR and the ﬁrst coding exon
(exon 1), which starts at 46827288 (Figure 1). NC exon
1 began at 78901bp upstream from the 50-UTR and NC
exon 4 was 16706bp upstream from the 50-UTR. There
were a total of ﬁve different splice variants found and the
relative abundance of each from LCls, normal colon, JP
and expressed sequence tags (ESTs) in the UCSC genome
browser (www.genome.ucsc.edu) is shown in the ﬁgure.
Deﬁning promoter regions
There were four areas that by 50-RACE and EST data
were candidates for being potential promoters (regions
A, B, C and D, Figure 1). Using Gene2Promoter
software (Genomatix), there were six regions that were
predicted to be promoters, including all four of the
regions predicted by 50-RACE. To identify the TSS, we
analysed published libraries of capped analysis gene
expression (CAGE) tags (Genomatix). CAGE tags help
identify transcriptional start sites on a genome-wide
scale and are short sequences that originate from the
50-end of mRNA transcripts. For this study, we designated
the TSS for each isoform as being the site of the most
50-CAGE tag. In the case of Promoter A, there were
four different potential TSS distributed over 56bp, sup-
ported by 28 CAGE tags. For Promoter C, there were
three TSS over a 30bp range supported by 63 CAGE
tags. The TSS for Promoter D was designated as the be-
ginning of the 50-UTR, which was conﬁrmed by the
Figure 1. Map of chromosome 18 near SMAD4, including NC and coding exons (top line) and ﬁve different splice variants found by 50-RACE
below. The number of 50-RACE clones found in various tissues and ESTs described in the UCSC genome browser (www.genome.ucsc.edu) are shown
at the right of each isoform. From the 149 ESTs described, only 43 of them contained the NC exons and 50-UTR, while the rest consisted only of
coding exons. The map positions of NC exons are: NC-exon 1:46748387–46748482; NC-exon 2:46754765–46754933; NC-exon 3:46808762–
46809033; NC-exon 4:46810582–46810991 and 50-UTR 46827288–46827414. Regions A, B, C, D are predicted to be the potential promoters
for these isoforms.
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from upstream NC exons. The TSS of Promoter B was
less certain, as it was based upon the most 50 transcript
found in our 50-RACE clones and ESTs in the UCSC
browser; there were no corresponding CAGE tags.
Activity of SMAD4 promoters in cell lines
Two of the four putative promoters had signiﬁcant
luciferase activity when transfected into different cell
lines. The region cloned as promoter A was the 736
bases immediately 50 to the TSS of NC exon 1 and the
ﬁrst 19 bases of NC exon 1, which was found to have
signiﬁcant activity in three cell lines (HEK-293, MCF-7
and CCL-247), but not in CRL-1459 (Figure 2a).
Promoter C was the 500 base region upstream from the
TSS of NC exon 4, plus 156bp of NC exon 4, which
showed signiﬁcant luciferase activity in all four cell lines
(Figure 2c).
The two other promoters (B and D; Figure 2b and d)
just showed modest activity in HEK-293 cells and even
less in CRL-1459 cells. The full construct for promoter
D spanned from 46826739 to 46827736 in the genomic
sequence and included the 50-UTR and a part of coding
exon 1.
Transcription factor binding sites
Comparative genomics using ElDorado software
(Genomatix), revealed several TFBS within each
promoter. Eight different species were analysed for con-
servation (monkey, chimpanzee, human, mouse, rat, cow,
pig and opossum). Using ModelInspector (Genomatix),
promoter A had eight TFBS which ﬁt into three-element
models that are conserved across species and had 42 CpGs
(Figure 3a). These TFBS include: homeodomain tran-
scription factors (HOMF); GATA binding factors
(GATA); human and murine EST factors (ETSF); activa-
tor-, mediator- and TBP-dependent core promoter
element for RNA polymerase II transcription from
TATA-less promoters (XCPE); CTCF and BORIS gene
family transcriptional regulators (CTCF); nuclear
Figure 2. Luciferase expression from the various deletion constructs of promoter A, B, C and D from the 4 cell lines, HEK-293, CRL-1459, MCF-7
and CCL-247. Deletion construct numbering is relative to the TSS; the last constructs of promoter A end at+19 relative to the TSS, for B at+473, C
at+156 from the TSS and for D at+449 into the ﬁrst coding exon. Note that there is no activity seen for promoter A in CRL-1459; that promoter B
was only evaluated in HEK-293 and CRL-1459 cells and that Promoter D was not evaluated in CCL-247 cells.
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(GLIF) and histone nuclear factor P (HNFP).
Promoter B had nine TFBS that were phylogenetically
conserved in the species examined: Activator/repressor
binding to transcription initiation site (YY1F); E-Box
binding factors (EBOX);Nuclear receptor subfamily 2
factors (NR2F); cellular and viral myb-like transcriptional
regulators (MYBL);nuclear factor 1 (NF1F);downstream
immunoglobulin control element (DICE);microphthalmia
transcription factor (MITF);Krueppel-like transcription
Figure 3. Sequences of each promoter region, including phylogenetically conserved TFBS as predicted by comparative genomics, where highlighted
nucleotides exhibit the highest conservation within the TFBS consensus sequence. The center line is the Chromosome 18 map, with the red vertical
lines representing the four promoters relative to SMAD4 coding exons. Red arrows designate TSS in each sequence, the numbers on the right of each
sequence are relative to the TSS; CG dinucleotides are shown in red. (A) Gene2promoter ID: GXP_57502, which overlaps with promoter A. There
were eight TFBS predicted to be phylogenetically conserved (with spacing demonstrated by the line with colored beads at top), represented by
colored highlighted regions at their sequences and names given to each color above: (HOMF, XCPE, ETSF, HNFP, GLIF, NRF1 and CTCF.
(B) GXP_1261977, which overlaps with promoter B. TFBS were predicted to be: YY1F, EBOX, NR2F, MYBL, NF1F, DICE, MITF, KLFS and
HESF. (C) GXP_57777, which overlaps with promoter C; six TFBS were predicted: ETSF, DMTF, SRFF, NRF1, BPTF and P53F. The sequences
with stars are predicted to be phylogenetically conserved between species, while the colored sequences without stars were predicted as TFBS by the
Genomatix software (but were not conserved) and were also evaluated by SDM. (D) GXP_1484970, which overlaps with promoter D. In promoter
D, 14 TFBS were predicted: RUSH, NEUR, HOMF, BRNF, OVOL, GREF, MYBL, ABDB, NKX6, SORY, HOXF, FKHD, P53F and PDX1.
The sequence within promoter D that has a single underline is the 50-UTR and the doubly underlined represents coding exon 1. The green arrow
is the translation start site.
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split complex (HESF).
Promoter C had six different TFBS that ﬁt into distinct
four-element models that are conserved across species and
55 CpGs (Figure 3c). These TFBS include: human and
murine EST1 factors (ETSF); serum response element
binding factor (SRFF); nuclear respiratory factor 1
(NRF1); cyclin D binding myb-like transcription factor
(DMTF); bromodomain and PHD domain TF (BPTF)
and the p53 tumor suppressor (P53F).
For Promoter D, there were 14 phylogenetically
conserved TFBS:SWI/SNF related nucleophospho-
proteins with a RING ﬁnger DNA binding motif
(RUSH);NeuroD, Beta2, HLH domain (NEUR),
homeodomain transcription factors (HOMF); Brn POU
domain factors (BRNF); OVO homolog-like transcription
factors (OVOL); glucocorticoid responsive and related
elements (GREF); cellular and viral myb-like transcrip-
tional regulators (MYBL); abdominal B-type
homeodomain transcription factors (ABDB); NK6
homeobox transcription factors (NKX6); SOX/SRY-sex/
testis determining and related HMG box factors (SORY);
paralog hox genes 1–8 from the four hox clusters A–D
(HOXF); fork head domain factors (FKHD); p53 tumor
suppressor (P53F) and pancreatic and intestinal
homeodomain transcription factor (PDX1). Note that all
of these factors except for MYBL fell within the ﬁrst
coding exon of SMAD4.
Promoter sequencing, screening for deletions, mutagenesis
of TFBS
There were 65 JP probands meeting the clinical criteria for
JP (24) who had no mutations identiﬁed by sequencing of
all coding exons of both SMAD4 and BMPR1A. Two
patients were found to have larger exonic deletions of
SMAD4 by MLPA, showing 50% decrease in ampliﬁca-
tion of the probes in the 50 region of the gene. Patient A
had a heterozygous deletion of a probe upstream of NC
exon 4 and all probes located within NC exon 4 and
Patient B, in addition to these same probes, also had
loss of all probes from coding exons 1–8 (Figure 4).
Using the CGH chip, the deletion of Patient A was con-
ﬁrmed and further characterized. Probes from position
46809737 through 46813229 had 50% decreased ampli-
ﬁcation, which meant the deletion included all of
Promoter C, NC exon 4 and at least 2kb of downstream
intron. Sequencing of Promoter C in the 65 JP probands
and 100 control patients revealed no mutations or
polymorphisms.
Due to the deletions found in two JP patients and its
functionality in our luciferase models, several potential
TFBS predicted by Genomatix and PromoterScan
software were evaluated by site-directed mutagenesis
(SDM) in Promoter C. When both thymine residues of
the vertebrate TATA binding protein factor of Promoter
C were changed to guanines by SDM, this resulted in only
10% of the luciferase activity compared to the wild-type
promoter (Figure 5). When other TFBS were changed by
2nt by SDM, the activity with mutation of one SP-1 site
was 38% and one zinc binding protein factor (ZBPF) site
was 37% (74 and 80% of the wild-type for two other
ZBPF sites). With respect to the phylogenetically conserved
sites, the luciferase activity with mutation of the ETSF1 site
was 36% of that seen for the wild-type vector, with
mutation of DMTF was 52% and minimal change was
observed with mutation of NRF1 (99% of wild-type),
SRFF (112%) and BPTF sites (99%). Interestingly, when
one base of the p53 site was changed, the luciferase activity
increased to 162% of the wild-type sequence.
ChIP-Seq, DNAseI and abundance of RNA isoforms
RNA Polymerase II ChIP-Seq results in MCF-7 cells and
ENCODE data (23) from HEK-293 cells revealed that
promoters A and C were the most active areas of RNA
Figure 4. Map of chromosome 18 in the vicinity of the SMAD4 gene. The top line shows the map positions and exons of SMAD4; the second line
the location of MLPA probes and the smaller line at left beneath, the location of CGH probes. The bar graph below shows MLPA results of two
patients, showing a 50% decrease in ampliﬁcation of the three probes within NC exon 4 and the probe located just 50 upstream of NC exon 4
(Patient A) and additionally up through coding exon 8 in Patient B.
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active than A and negligible activity was seen for
promoters B and D (Figure 6). ENCODE DNaseI data
in MCF-7 cells and ﬁbroblasts demonstrated the same
pattern. These data support the luciferase results and
further validates the importance of these two promoters.
The relative abundance of different NC RNA isoforms
were evaluated by slot blot hybridization to RNA
derived from HEK-293, CRL-1459 and MCF-7 cells
using probes spanning contiguous NC segments (except
the last isoform). The most common isoform found by
this method in all three lines was that of NC exon 1
splicing into the 50-UTR, which is presumed to be under
the control of Promoter A. The second most common
was NC exon 4 splicing into the 50-UTR, which would
be just downstream of Promoter C (Supplementary
Table S1).
DISCUSSION
The complexity of the promoters for SMAD4 has been
under-appreciated until now. Minami et al. (16) evaluated
1285 bases immediately upstream of the 50-UTR of
SMAD4 plus 45 in the 50-UTR (comparable to Promoter
D in this study) and described a peak luciferase activity of
38 light units compared to the control of 2.2 light units.
However, this region lacked typical promoter region char-
acteristics, such as high CG content (CpG islands) or a
TATA-box, but did have some TATA-like structures (TA
AAAT) and other potential transcriptional binding sites.
Current evidence suggests that low CG content promoters
are more likely to be cell speciﬁc, while CG rich are more
likely to be ubiquitously expressed (25).
Zhou et al. (17) found that six endometrial carcinoma
specimens had LOH of chromosome 18q21 markers and
altered transcription of SMAD4 and sequencing for
Figure 6. Map of Chromosome 18, with (lines from top to bottom): the coding exons of SMAD4; promoter regions; results of ChIP-Seq for RNA
Polymerase II in MCF-7 cells; DNase I hypersensitivity sites in MCF-7 cells (from ENCODE data); ChIP-Seq for RNA Polymerase II in HEK-293
cells (from ENCODE data); DNase I hypersensitivity sites in ﬁbroblasts (from ENCODE data) and the density of CG dinucleotides. The areas under
promoters A and C are highlighted in gray.
Figure 5. Luciferase activities in HEK-293 cells after mutating selected TFBS in promoter C. The wild-type luciferase activity is compared to 11
different mutant constructs: ETSF; DMTF; SRFF; VTBP; SP1F: Sp/KLF family of transcription factors; ZBPF: Zinc ﬁnger transcription factors
(three different sites); NRF1; BPTF; P53F: p53 tumor suppressor.
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in two patients. Functional assays (chloramphenicol
acetyltransferase) of promoter activity revealed these sub-
stitutions led to signiﬁcantly reduced activity relative to
the wild-type sequence. We found that promoter D had
minimal activity in the four different cell lines we tested,
despite the inclusion of the 50-UTR and part of coding
exon 1 where the majority of predicted TFBS were
concentrated and similar results were obtained when the
50-UTR and this portion of exon 1 were left out (data not
shown). The lack of RNA polymerase II binding sites and
DNaseI sites around promoter D support the notion that
this is not a very active site of transcription, at least in the
cell lines examined.
Promoter C was found to have signiﬁcant luciferase
activity in all four cell lines evaluated and this region
has sparked interest from investigators in the past. This
began with Roth et al. (18) who screened an overlapping
region of 700bp from position 46810540 to 46811239 for
methylation in colorectal cancer specimens. They selected
this region because it was CG-rich and an unpublished
manuscript by Hagiwara et al. apparently examined the
sequence immediately upstream from a newly discovered
NC exon. The region they looked at is primarily within
and downstream of NC exon 4 (which starts at position
46810582 and ends at 46810991). However, it did
contain 42 bases of promoter C upstream from the TSS
and while these bases were found to have negligible
luciferase activity in our deletion constructs, the
sequence examined would have contained four of six
phylogenetically conserved sites. Roth et al. did not ﬁnd
methylation in 42 colorectal cancer samples, but these
studies may have been inconclusive since this promoter
appears to include a larger sequence upstream, as
evident by our luciferase models.
Onwuegbusi et al. (19) also screened the segment
studied by Roth et al. and found that 70% of esophageal
adenocarcinomas had methylation. The same region was
evaluated in prostate cancer specimens and although no
evidence of methylation was found in benign prostatic
hypertrophy samples, 45% of prostate cancers had methy-
lation. Furthermore, they found that patients with lymph
node metastasis had a higher incidence of methylation
(63%). They also looked for mutations, but none were
identiﬁed within the 40 bases of promoter C that were
screened, or in the sequences of NC exon 4 (20). Again,
these studies examined primarily NC exon 4 and the
intron downstream and therefore, the consequence of
ﬁnding methylated CpGs here upon tumor formation is
unclear.
Ando et al. screened sequences between 46810524 and
46810769 for methylation in CRC specimens and found
none. The area they studied is mostly within NC exon 4,
with only 58 bases upstream of the TSS included (26).
Wang et al. (27) examined a larger area of promoter C
by looking at a region of 200 bases upstream from
position 46810611, which was believed to be the TSS of
NC exon 4 (although current evidence suggests the TSS is
now at position 46810581). They screened gastric carcin-
oma specimens and found that 4 specimens out of 75 (5%)
had methylation that was associated with decreased
expression of SMAD4. Kloth et al. (9) looked at an
even larger area of promoter C in cervical cancer speci-
mens, by screening for methylation including up to 270
bases upstream from the TSS, to 155 bases downstream
and they found no evidence of methylation. This study did
not include the other 255 bases upstream to position
46809882. It remains to be determined whether the inci-
dence of methylation in gastric and cervical cancer
patients would have been higher if these additional bases
had been screened. It should also be noted that prior to
the current study, there have been no luciferase studies
published that conﬁrmed this region had promoter
activity.
In the cell lines tested, Promoters A and C were the
most functionally active. Promoter C has a greater
number of mRNA isoforms that might potentially be
regulated by it, a higher CpG content relative to
promoter A and showed luciferase activity in all four
cell lines, while promoter A had no promoter activity in
a normal colon ﬁbroblast cell line (CRL-1459). ChIP-Seq
and DNaseI data revealed a greater number of sites at
promoter C, but the most abundant RNA isoform
found by hybridization was one predicted to be under
the control of promoter A. In contrast, none of these
studies suggested an important role for either promoter
B or D in the cell lines we tested. However, different pro-
moters may play distinct roles in various tissues, during
stages of development, or physiologic conditions.
Presumably this activity is inﬂuenced by the differing
context and abundance of transcription factors which
are present in each circumstance. Analyzing promoter C
with MatInspector (www.genomatix.de/products/
MatInspector) revealed several potentially important
TFBS that could be involved in regulation of SMAD4.
From the  500bp to the  414bp construct, there was a
>45–50% drop in luciferase activity and this region has
one zinc ﬁnger homeodomain transcription factor binding
site (ZFHX), an AP-2 site, an SP-1 site, several C-abl
DNA binding sites (CABL), ZBPF sites and a TATA
box. This area was not examined in all of the previous
studies attempting to screen the SMAD4 promoter for
methylation. Between the  500bp and  34bp constructs,
there was a loss of >85–95% of the luciferase activity in
both CRL-1459 and HEK-293 cell lines. Between the
 234bp and  34bp deletion constructs, there is an add-
itional SP-1 site, six ZBPF, two AP-2 sites, a CABL site
and a possible core promoter element for RNA pol II
transcription binding site for TATA-less promoters
(Figure 3). Furthermore, phylogenetic data show that
there are multiple TFBS that are conserved between
species, which is not only a testament to the importance
of these regions, but also provides insight into the tran-
scriptional regulatory elements that might play a role in
the expression of this important tumor suppressor gene.
We focused further attention on the sequence of Promoter
C because more of the mRNA isoforms are likely
regulated by this region and the deletion seen in one JP
patient affected this region. Further analysis by SDM
showed how important the TATA box, ZBPF and the
SP-1 sites could be in inﬂuencing the transcription of
5376 Nucleic Acids Research, 2011,Vol.39, No. 13SMAD4, for when these sites were mutated the promoter
activity was signiﬁcantly diminished (Figure 5).
Although screening of our 65 JP probands revealed no
germline mutations within Promoter C, we did ﬁnd two JP
patients with germline deletions affecting this region, one
of which involved only promoter C and NC exon 4 (and
none of the coding exons). Aretz et al. (28) also found four
JP patients with deletion of these four MLPA probes, but
they also had deletions involving all the coding exons as
well. These data suggest that promoter alterations play a
role in the genesis of JP, as recently reported for BMPR1A
(29), and therefore, further evaluation of promoter A in JP
patients will be of interest. Whether epigenetic inactivation
of the normal copy of SMAD4 leads to polyp formation is
another important question to be examined in JP patients.
Now that these promoter regions have been characterized,
follow-up studies in colon, gastric, cervical, pancreatic and
other sporadic cancers will be imperative to deﬁne their
importance in tumorigenesis.
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